These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26915397)

  • 1. Analysis of aluminium in rat following administration of allergen immunotherapy using either aluminium or microcrystalline-tyrosine-based adjuvants.
    McDougall SA; Heath MD; Kramer MF; Skinner MA
    Bioanalysis; 2016 Mar; 8(6):547-56. PubMed ID: 26915397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminium in allergen-specific subcutaneous immunotherapy--a German perspective.
    Kramer MF; Heath MD
    Vaccine; 2014 Jul; 32(33):4140-8. PubMed ID: 24892252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
    Rask C; Lund L; Lund G; Heydenreich B; Wurtzen P; Bellinghausen I; Saloga J; Lund K
    Clin Exp Allergy; 2012 Sep; 42(9):1356-68. PubMed ID: 22925322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio.
    Jung K
    Allergy; 2011 Jul; 66 Suppl 95():41-3. PubMed ID: 21668852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al.
    Flarend RE; Hem SL; White JL; Elmore D; Suckow MA; Rudy AC; Dandashli EA
    Vaccine; 1997; 15(12-13):1314-8. PubMed ID: 9302736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contact allergy to aluminium in patients hyposensitized with aluminium-containing hyposensitizing extracts.
    Hindsén M
    Contact Dermatitis; 2005 Nov; 53(5):301-2. PubMed ID: 16283911
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.
    Pfaar O; Jung K; Wolf H; Decot E; Kleine-Tebbe J; Klimek L; Wüstenberg E
    Allergy; 2012 May; 67(5):630-7. PubMed ID: 22385366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and characterisation of aluminium-containing nanoparticles in Chinese noodles by single particle ICP-MS.
    Loeschner K; Correia M; López Chaves C; Rokkjær I; Sloth JJ
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2018 Jan; 35(1):86-93. PubMed ID: 28934065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of brain regional distribution of aluminium in rats via oral and intraperitoneal administration.
    Sánchez-Iglesias S; Soto-Otero R; Iglesias-González J; Barciela-Alonso MC; Bermejo-Barrera P; Méndez-Alvarez E
    J Trace Elem Med Biol; 2007; 21 Suppl 1():31-4. PubMed ID: 18039493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does allergen-specific immunotherapy induce contact allergy to aluminium?
    Netterlid E; Hindsén M; Siemund I; Björk J; Werner S; Jacobsson H; Güner N; Bruze M
    Acta Derm Venereol; 2013 Jan; 93(1):50-6. PubMed ID: 22948339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations.
    Vogelbruch M; Nuss B; Körner M; Kapp A; Kiehl P; Bohm W
    Allergy; 2000 Sep; 55(9):883-7. PubMed ID: 11003454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Subcutaneous nodules and sensitivity to aluminum in patients undergoing hyposensitivity immunotherapy].
    García-Patos V; Alomar A; Lleonart R; Cistero A; Matias-Guiu X
    Med Cutan Ibero Lat Am; 1990; 18(2):83-8. PubMed ID: 2145483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with an optimized allergen to adjuvant ratio under routine practice conditions: a noninterventional observational study.
    Hauswald B; Wolf H; Becker F; Becker S; Schnitker J; Wüstenberg E
    J Investig Allergol Clin Immunol; 2013; 23(7):471-7. PubMed ID: 24654311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent subcutaneous nodules after immunotherapy injections for allergic asthma.
    Ozden MG; Kefeli M; Aydin F; Senturk N; Canturk T; Turanli AY
    J Cutan Pathol; 2009 Jul; 36(7):812-4. PubMed ID: 19519616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous nodules in a patient hyposensitized with aluminium-containing allergen extracts: a microanalytical study.
    Morroni M; Barbatelli G; Carboni V; Sbarbati A; Cinti S
    Anal Cell Pathol; 1995 Oct; 9(3):235-41. PubMed ID: 8562462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy.
    Netterlid E; Hindsén M; Björk J; Ekqvist S; Güner N; Henricson KA; Bruze M
    Contact Dermatitis; 2009 Jan; 60(1):41-9. PubMed ID: 19125720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice.
    Freiberger SN; Leuthard DS; Duda A; Contassot E; Thallmair M; Kündig TM; Johansen P
    Eur J Pharm Sci; 2018 Mar; 115():362-368. PubMed ID: 29410031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminium (Al) speciation in serum and urine after subcutaneous venom immunotherapy with Al as adjuvant.
    Michalke B; Kramer MF; Brehler R
    J Trace Elem Med Biol; 2018 Sep; 49():178-183. PubMed ID: 29496416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
    Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
    Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.